PMID: 1491Nov 1, 1975

Phenylbutazone-warfarin interaction in the dog

The Journal of Pharmacy and Pharmacology
K A Bachmann, A M Burkman

Abstract

The administration of phenylbutazone together with warfarin to dogs resulted in an elevation of the free fraction of warfarin in the plasma from 2-6 to 8-0% thus providing direct support for the notion that phenylbutazone induced inhibition of warfarin binding to plasma proteins. This inhibition as evaluated by a kinetic method was accompanied by a two-fold decrease in the plasma half-life of warfarin from 18-4 h in control animals to 9-6 h in phenylbutazone-treated animals. Marked increases in warfarin-induced hypoprothrombinaemia were observed when at doses up to 8 mg kg-1 (orally) it was given with phenylbutazone (50 mg kg-1, orally). The unbound fraction of warfarin in canine plasma ranged from 1-7 to 4-3% indicating individual differences in the extent of the plasma binding of warfarin in the dog.

References

Nov 1, 1972·Journal of Pharmaceutical Sciences·H W JunP L Hsu
Jun 1, 1974·The Journal of Clinical Investigation·R J LewisW Schary
Dec 1, 1970·Biochemical Medicine·R J LewisM Carlstrom
Sep 21, 1968·The Veterinary Record·G J Hovell
Jan 1, 1969·Clinical Pharmacology and Therapeutics·R NagashimaG Levy
Jul 7, 1967·Biochemical Pharmacology·H M Solomon, J J Schrogie

Citations

Aug 1, 1976·Journal of Pharmaceutical Sciences·F W Goodhart, M L Eichman
Oct 1, 1977·Toxicology and Applied Pharmacology·K A Bachmann, J Tarloff
Dec 1, 1979·Journal of Pharmacokinetics and Biopharmaceutics·W Schmidt, E Jähnchen
Jan 18, 2019·Journal of Veterinary Emergency and Critical Care·Marie-Claude BlaisClaire R Sharp
Jul 1, 1982·The Journal of Pharmacy and Pharmacology·H SatohS Satoh

Related Concepts

Canis familiaris
Drug Interactions
Half-Life
Inherited Factor II Deficiency
Fenilbutazon
Plasma Protein Binding Capacity
Prothrombin
Gen-Warfarin

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

The Journal of Pharmacy and Pharmacology
D AttwoodS C Perry
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
R D SmythT Herczeg
Journal of Pharmaceutical Sciences
J C LooI J McGilveray
© 2021 Meta ULC. All rights reserved